Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
PBLA Panbela Therapeutics
0.097
+0.001+1.04%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
ROIC
-450.04% -356.831% -129.24% -426.575% -29.79% -162.843% -12.27% -108.514%
ROE
-1,902.88% -1301.543% -3,074.35% -5918.797% -29.53% -162.993% -12.01% -108.628%
ROA
-503.01% -343.037% -245.07% -454.635% -21.91% -115.544% -21.41% -89.354%
Efficiency Ratios
ROA 5 Year Average
-- -- -- -- -- -- 12.12% -422.816%
Profitability Ratios TTM
Financial Health Ratios
Total Assets to Common Equity
-- -- -- -- 43.67% 168.485% 8.51% 126.048%
Current Ratio
-97.98% 0.2221 -89.28% 0.5573 -73.91% 1.7602 -35.42% 4.6162
Quick Ratio
-98.86% 0.1241 -90.77% 0.4659 -73.59% 1.7198 -33.07% 4.582
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- -- 0.000%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
CEO: Dr. Jennifer K Simpson, PhD
Market: NASDAQ
Listing Date: 08/28/2020
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist